Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial

Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki +2 more·2021·Diabetes Care
DOI 10.2337/dc20-2604

Cited by (125)

Items 101–125 of 125

  1. Cardiovascular Magnetic Resonance-Estimated Pulmonary Capillary Wedge Pressure, Congestion Markers, and Effect of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction and Dysglycaemia (SUGAR-DM-HF)
    Joanna Osmanska, Kieran F. Docherty, Colin Berry, Pardeep S. Jhund, Kenneth Mangion, Patrick Barry Mark, John J.V. McMurray, Giles Roditi, Naveed A. Sattar, Mark Colquhoun Petrie et al. · 2025 · European Journal of Heart Failure
  2. The PVAT–MAMs Axis in Atherosclerosis: A Hypothesis-Driven Cross-Scale Conceptual Framework
    Sixiang Zhang, Yuhan Li, Yingrui Wang, Bingqi Guo, Zixuan Liu, Zheng Liu · 2026 · International Journal of Molecular Sciences
  3. Salt and chronic kidney disease
    Jacob Murray, Roos F.J. Marsman, Rik Olde Engberink, Liffert Vogt · 2026 · Nature Reviews Nephrology
  4. Candida glabrata Prostatitis: A Rare Case in a Patient With Type 2 Diabetes Mellitus on Dapagliflozin Treatment
    Elena Gloria Torres García, Cristina Marcelo, Paula Navarro-Carrera, Alejandro Díez Vidal, Beatriz Díaz‐Pollán · 2026 · Case Reports in Infectious Diseases
  5. Mechanisms of renoprotective action of sodium-glucose cotransporter-2 inhibitors (gliflozins): a clinician’s view
    Ya.M. Lutay, Alexander N. Parkhomenko · 2023 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
  6. Cardiovascular Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure—Does the Story Begin and End With the Kidney?
    Ravi B. Patel · 2023 · JAMA Cardiology
  7. The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals
    Britt Eveline Wever, Rosalie Annemien Scholtes, Charlotte M. Mosterd, Anne C. Hesp, Mark M. Smits, Hiddo J.L. Heerspink, Daniël H. van Raalte · 2025 · Journal of Nephrology
  8. The effects of empagliflozin on kidney function and glucose metabolism in acute kidney injury
    Lars I.P. Snel, Maartina J P Oosterom-Eijmael, Jeroen Hermanides, Daniël H. van Raalte, Abraham Hendrikus Hulst · 2025 · Journal of Clinical Anesthesia
  9. SGLT2 inhibitors in the prevention of nephrolithiasis: a comprehensive review
    Marco Lombardi, Pamela Gallo, Selene Laudicina, Lisa Buci, Francesco Giudici, Alfonso Baldoncini, Simone Agostini, Alfonso Crisci, Stefano Michelassi · 2025 · Giornale di Clinica Nefrologica e Dialisi
  10. Neues zu Hypertonie und Diabetes
    Tom H. Lindner · 2021 · Der Diabetologe
  11. SGLT2-Inhibitoren bewirken keine erhöhte Natriumexkretion: DAPASALT-Studie
    Britta Brudermanns · 2021 · Diabetologie und Stoffwechsel
  12. Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors
    Costanza Gaudio, Marta Seghieri, Chiara Merciai, Claudia Colombi, Giuseppe Luciano Spatoliatore, Cristiana Maria Baggiore, Alberto Rosati · 2023 · Experimental and Clinical Endocrinology & Diabetes
  13. Improving kidney protection in patients with type 2 diabetes
    Annemarie B. van der Aart‐van der Beek · 2023
  14. Mechanisms of SGLT2 inhibition in the kidney
    Taha Sen · 2023
  15. Dapagliflozin did not increase in serum K in advanced CKD in spite of initial eGFR decline
    Waka Mitani, Yukimasa Iwata, Midori Kobayashi, Shoki Notsu, Madoka Morimoto, Masafumi Yamato · 2024 · Research Square
  16. The Effect of SGLT2 Inhibitor on Renal Anemia in Patients with Moderate to Severe Diabetic Kidney Disease
    Chuanlei Li, Jack Kit‐Chung Ng, Gordon Chun‐Kau Chan, Winston WS Fung, Kai Ming Chow, Cheuk‐Chun Szeto · 2024 · Research Square
  17. Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research
    小寒 夏 · 2024 · Advances in Clinical Medicine
  18. Renal and systemic hemodynamic effects of empagliflozin: Three randomized, double blind, placebo controlled cross-over trials
    Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose · 2024 · medRxiv
  19. Additional file 1 of Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes
    Khan, Muhammad Shahzeb, Janice P. Lea · 2024 · Figshare
  20. Is thirst the missing physiological link between SGLT2 inhibitors and reduced nephrolithiasis risk?
    Marco Lombardi, P. Beltrami, Bernardo Martini · 2026 · Clinical Kidney Journal
  21. Targeting kidney disease in type 1 diabetes: progress and promise
    Marcel H. A. Muskiet, D. Cherney · 2026 · Expert Review of Endocrinology & Metabolism
  22. Safety and Tolerability of SGLT2 Inhibitors
    Marcel H.A. Muskiet, Daniël H. van Raalte, Mark M. Smits · 2026 · Handbook of experimental pharmacology
  23. The potential benefit of sodium glucose cotransporter (SGLT)-2 inhibitors in liver cirrhosis: A mini review
    Michelle Spaan, Abraham Stijn Meijnikman, Daniël H. van Raalte, Joost P.H. Drenth · 2026 · Therapeutic Advances in Gastroenterology
  24. Lithium Concentrations After Initiation or Discontinuation of SGLT2 Inhibitors in Psychiatric Inpatients
    Pierre Duranleau-Gagnon, Laurent Béchard, Katryn Langlois-Parisé, Marie‐France Demers, Olivier Corbeil · 2026 · Journal of Clinical Psychopharmacology
  25. Serum Lithium After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
    Christopher Rohde, Søren Dinesen Østergaard, Klavs Würgler Hansen · 2026 · Journal of Clinical Psychopharmacology